Takahashi, Shunji
Kobayashi, Takayuki
Tomomatsu, Junichi
Ito, Yoshinori
Oda, Hisanobu
Kajitani, Tatsuhiro
Kakizume, Tomoyuki
Tajima, Takeshi
Takeuchi, Hiromi
Maacke, Heiko
Esaki, Taito
Clinical trials referenced in this document:
Documents that mention this clinical trial
LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
https://doi.org/10.1007/s00280-016-3214-4
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 20 October 2016
Accepted: 29 November 2016
First Online: 9 December 2016
Compliance with ethical standards
:
: Shunji Takahashi received research funding from Novartis; Taito Esaki received research funding from Eli Lilly, Taiho, Novartis, Daiichi Sankyo, AstraZeneca, Bayer, Merck Serono, Ono, Boehringer, MSD, and Astellas; Yoshinori Ito received research funding from Chugai, Novartis, Parexel, and EPS; Shunji Takahashi received honoraria from Novartis; Taito Esaki received honoraria from Yakult, Chugai, Eli Lilly, Taiho, and Merck Serono; Yoshinori Ito received honoraria from Chugai, Novartis, Esai, and Taiho; Tomoyuki Kakizume, Takeshi Tajima, Hiromi Takeuchi, and Heiko Maacke are employees of Novartis; Takayuki Kobayashi, Junichi Tomomatsu, Hisanobu Oda, and Tatsuhiro Kajitani have no conflict of interest. The study was designed under the responsibility of and funded by Novartis; Novartis collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.